Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy
Ipsen is looking to expand its paediatric medication portfolio and has signed a licensing agreement potentially worth $461m with Day…
Ipsen is looking to expand its paediatric medication portfolio and has signed a licensing agreement potentially worth $461m with Day…
Johnson and Johnson (J&J) Innovative Medicine has decided to halt the development of its epilepsy drug, three months after a…
England’s National Health Service (NHS) has said that multiple sclerosis patients could have their hospital treatment time slashed following the…
Semnur Pharmaceuticals has signed a letter of intent to go public via a merger with the special purpose acquisition company…
As Eli Lilly’s Kisunla (donanemab) enters the Alzheimer's treatment space, its leading competitor Biogen is undergoing therapy diversification after completing…
TauRx Pharmaceuticals has filed a marketing authorisation application (MAA) with the UK Medicines and Healthcare products Regulatory Agency, seeking approval…
Eisai and Biogen have announced the introduction of LEQEMBI (lecanemab) for the treatment of Alzheimer's disease (AD) in China. The…
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application (NDA)…
Ascidian Therapeutics has entered a research partnership and licensing agreement with Roche to discover and develop RNA exon editing therapies…
The US Food and Drug Administration (FDA) has signed off on a ready-to-use formulation of vigabatrin developed by Pryos Pharmaceuticals…